TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects (11-17 years of age inclusive) who have given their written assent and whose parents or legal guardians have given written informed consent at the time of enrollment~* who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period)~* in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.~Exclusion Criteria:~* History of any serogroup B meningococcal vaccination~* Current or previous, confirmed or suspected disease caused by N. meningitidis~* Exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment~* Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥ 38.0 °C) within the previous day~* Antibiotic use within 3 days (72 hours) prior to enrollment~* Pregnancy or nursing (breastfeeding) mothers~* Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry~* Any serious chronic or progressive disease, Known or suspected impairment/alteration of the immune system~* Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days~* History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- MenB Lot 1 (Type: EXPERIMENTAL): MenB vaccine Lot 1: 2 doses administered 1 month apart
- MenB Lot 2 (Type: ACTIVE_COMPARATOR): MenB vaccine Lot 2: 2 doses administered 1 month apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent~* Men or women patients ≥ 40 years of age~* Diagnosis of COPD with symptoms for more than 2 years and there is a history of at least one COPD exacerbation requiring a course of oral steroids and/or antibiotics within 1-12 months before Visit 2~* Forced Expiratory Volume in 1 second (FEV1) ≤50% of predicted normal value, pre-bronchodilator and Forced Expiratory Volume in 1 second (FEV1) / Forced Vital Capacity (FVC) \< 70%, pre-bronchodilator~* Total symptom score of 2 or more per day for at least half of run-in period (breathing, cough and sputum scores from the diary card) and complete morning recordings of Digital Peak Flow Meter data at least 7 out of the last 10 days of the run-in period~Exclusion Criteria:~* A history of asthma and seasonal allergic rhinitis before 40 years of age~* Patients who have experienced exacerbation of COPD requiring hospitalisation and /or emergency room treatment and/or a course of oral steroids and/or intravenous corticosteroids and/or antibiotics within 4 weeks prior to Visit 2 and/or during run-in period~* Patients with relevant cardiovascular disorder judged by the investigator~* Patients with glaucoma, prostatic hyperplasia or bladder-neck obstruction judged by the investigator~* Women who are pregnant, breast-feeding or of child-bearing potential judged by the investigator

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
- 2 (Type: OTHER): ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completes the qualifying clinical study final visit~* In the opinion of the principal investigator (PI), has been generally compliant with study requirements during the qualifying study, or must be considered eligible to enroll in PIPF-012 by the InterMune medical monitor~* Is able to provide informed consent and comply with the requirements of the study~Exclusion Criteria:~* Is pregnant or lactating~* Has known hypersensitivity to any of the components of the study drug~* Starts participation in another interventional clinical trial between the end of participation in the qualifying InterMune clinical trial and entry into PIPF-012~* Receives concomitant and/or excluded medications as defined in the protocol~* Permanently discontinues study drug during the qualifying study for any reason before study completion

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 84 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): pirfenidone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male adults (aged 18 to 65 years) with Haemophilia A (all severity levels) who currently use FVIII treatment either prophylactically or on-demand using traditional factor VIII delivery mechanisms.~* Patients advised for any reason by their physician to switch to a new factor VIII delivery device, namely FuseNGO, before receiving any details about this study or Patients who requested to be treated with a new factor VIII delivery device namely FuseNGO, before receiving any details about this study.~Exclusion Criteria:~* Patients not previously recommended by their physician to switch to this new factor VIII delivery system or Patients who did not previously ask their physician to be switched to this new factor VIII delivery system.~* Patients for which it is anticipated that 10 infusions will not occur in the 12 months following their inclusion in the study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Device (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin for Prevention of Metabolic Side Effects of Olanzapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 year~* First episode schizophrenia (DSM-IV-TR)~* Ability to take medicine orally~* Eligible for starting olanzapine~Exclusion Criteria:~* Married women who are at reproductive age~* History of taking olanzapine in the recent 3 months~* History of allergy or intolerance to olanzapine~* History of significant head trauma ( causing loss of consciousness more than 5 minutes or neurological or cognitive sequels)~* Liver, kidney, cerebrovascular or cardiovascular disease~* Diabetes, metabolic syndrome~* Cancer~* Using antiepileptic (other than benzodiazepines for sleep) , antihypertensive, anticoagulant, anti-platelet drugs~* Using inhibitors or stimulants of hepatic isoenzymes that metabolize melatonin or olanzapine (e.g. omeprazole. rifampin, fluvoxamine, ciprofloxacin, carbamazepine, modafinil)~* Delirium~* Need for administration of other antipsychotics~* Substance abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (with the same shape and taste as melatonin) at 9 pm as control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: At-home Transcranial Alternating Current Stimulation During Multitasking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking~* Grade 12 or more education~* Normal or corrected to normal vision and hearing~* Ability to complete cognitive tasks~* Ability to cooperate and comply with all study procedures~* Ability to tolerate tACS~Exclusion Criteria:~* Neurological or psychiatric disorders~* Family history of epilepsy~* History of seizures~* Prior head trauma~* Pregnant~* Implanted electronic devices (e.g., pacemaker)~* IQ \< 80~* Taking psychotropic medication~* Taking anti-depressants or anti-anxiety medication~* Substance abuse~* Color blind~* Glaucoma~* Macular degeneration~* Amblyopia~* Strabismus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Verum Stimulation (Type: EXPERIMENTAL): This group will receive 6-Hz tACS
- Frequency Control (Type: ACTIVE_COMPARATOR): This group will receive 1-Hz tACS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Main Inclusion Criteria:~* Body mass index between 18.0 and 32.0 kg/m2 inclusive.~* History of perennial allergic rhinitis to house dust mite for more than 1 year.~* Positive Skin Prick Test (SPT) for Dermatophagoides pteronyssinus (der p) allergen at screening or within 12 months prior to the screening visit.~Main Exclusion Criteria:~* Any clinically relevant abnormal findings in physical examination, clinical chemistry, hematology, urinalysis, vital signs, lung function at screening visit, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study or may influence the results of the study, or the subject's ability to participate in the study.~* Use of any medication considered to have an influence on the outcome of the study during the EEC session, at the discretion of the Investigator and/or designee.~* Recent nasal ulcers, mucosal erosion, nasal surgery, or nasal trauma, that might interfere with study results as determined by the Investigator and/or designee.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (Type: EXPERIMENTAL): Treatment sequence for the 3 treatment exposure visits is ABC.
- Sequence 2 (Type: EXPERIMENTAL): Treatment sequence for the 3 treatment exposure visits is BCA.
- Sequence 3 (Type: EXPERIMENTAL): Treatment sequence for the 3 treatment exposure visits is CAB.
- Sequence 4 (Type: EXPERIMENTAL): Treatment sequence for the 3 treatment exposure visits is ACB.
- Sequence 5 (Type: EXPERIMENTAL): Treatment sequence for the 3 treatment exposure visits is BAC.
- Sequence 6 (Type: EXPERIMENTAL): Treatment sequence for the 3 treatment exposure visits is CBA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.~Exclusion Criteria:~* Subjects with clinically significant cardiovascular disease in the past 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Had received two-dose priming vaccination in previous phase I trial~* Be able to show legal identity card for the sake of recruitment~* Be able to understand and sign the informed consent.~Exclusion Criteria:~* Woman： Who breast-feeding or planning to become pregnant during the study~* Any history of allergic reactions to vaccines or eggs~* Autoimmune disease or immunodeficiency~* Diabetes mellitus (type I or II), with the exception of gestational diabetes~* Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years~* Hypertension that was not well controlled by medication or is more than 145/95 mmHg at enrollment~* Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study~* Guillain-Barre Syndrome~* Women subjects with positive urinary pregnancy test~* Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months~* History of any blood products administration within 3 months before the dosing~* Administration of any other investigational research agents within 30 days before the dosing~* Administration of any live attenuated vaccine within 30 days before the dosing~* Administration of subunit or inactivated vaccines, e.g. pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing~* Be receiving anti-TB prophylaxis or therapy currently~* Axillary temperature \>37.0 centigrade at the time of dosing~* Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment~* Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 61 Years
- Healthy Volunteers: t

Study Arms:
- No.1: 1.25 ug (Type: EXPERIMENTAL): None
- No.2: 2.5 ug (Type: EXPERIMENTAL): None
- No.3: 5.0 ug (Type: EXPERIMENTAL): None
- No. 4: 10 ug (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients chronically infected with hepatitis C virus (HCV) genotype 1 or 4~* HCV RNA viral load of ≥100,000 IU/mL~* No previous exposure to interferon, pegIFNα, or RBV~* Results of a liver biopsy demonstrating absence of cirrhosis obtained ≤24 months prior to randomization. Compensated cirrhotics with Hepatitis C virus genotype 1 infection are eligible, but will be capped at 10% of the randomized study population (biopsy can be from any time period prior to randomization)~* Findings on ultrasound, computed tomography scan, or magnetic resonance imaging 12 months prior to randomization that do not demonstrate evidence of hepatocellular carcinoma~* Body mass index of 18 to 35 kg/m\^2~Exclusion Criteria:~* Positive for hepatitis B or HIV-1/HIV-2 antibody at screening~* Evidence of a medical condition associated with chronic liver disease other than HCV~* Evidence of decompensated cirrhosis based on radiologic criteria or biopsy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg) (Type: EXPERIMENTAL): None
- Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg) (Type: EXPERIMENTAL): None
- Placebo plus peg-interferon alfa-2a and ribavirin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age~* Have been histologically diagnosed with invasive adenocarcinoma of the prostate, at clinical stage T1-T3 (as determined by a biopsy taken within 9 months of the screening visit)~* Be scheduled for radiation therapy (XRT) by means of IMRT~Exclusion Criteria:~* Any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject has been disease free for a minimum of 5 years~* Prior radical prostatectomy~* Prior cryosurgery or radiotherapy for prostate cancer, or other local therapy for prostate cancer~* Prior radiotherapy to the pelvis, including brachytherapy~* History of prior surgery involving the rectum or anus~* Prior surgical procedure involving the peri-rectal and/or peri-prostatic area

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- balloon group (Type: EXPERIMENTAL): Marking + balloon implantation + IMRT
- Control group (Type: SHAM_COMPARATOR): Marking + IMRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects in the following groups: An elderly subject at least 65 years of age. At least 5 subjects must be at least 75 years of age OR A matched-control subject between 18 and 45 years of age, inclusive~* BMI ≥18.0 kg/m2 and ≤35.0 kg/m2~Elderly Group~* Medical history, physical examination, and laboratory results consistent with stable health (as determined by the Investigator)~Control Group~* Medically stable with no clinically significant abnormalities~Exclusion Criteria:~* Significant, uncontrolled, or life-threatening condition or organ or system condition or disease (eg, impaired cognitive status, respiratory insufficiency, advanced malnutrition)~* Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antibody test result~* Previous inclusion in a TR-701 FA or TR-701 clinical study~* ECG finding of QTc interval \>500 msec, or other clinically significant ECG abnormality at Screening~* Female subjects whom are pregnant, lactating or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Elderly subjects (65 or older) (Type: EXPERIMENTAL): None
- Younger adults (18-45 years old) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic kidney disease with estimated GFR of 30 mL/minute or more.~* Patients receiving stable dose of ACE inhibitor or Angiotensin receptor blockers for at least one month.~* Patients not currently hypertensive more than 180/110 mmHg by clinic blood pressure.~* Hemoglobulin A1C\< 11%~Exclusion Criteria:~* Patients taking vitamin D analogs~* Calcium\> 10 mg/dL~* Phosphorus\>6 mg/dL~* Patients with anticipated need of dialysis in the next 6 weeks~* Patients unstable in the opinion of the investigator~* Patients who have emergent need for starting IV iron~* Patients who will be started on statins within the next 6 weeks~* Patients currently taking PDE5 inhibitors~* Patients allergic to radiocontrast, Zemplar or who can not take nitroglycerin~* Patients known to be HIV positive~* Patients who can not give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1 mcg paricalcitol
- 2 (Type: ACTIVE_COMPARATOR): 2 mcg paricalcitol
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete